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Endometriosis is an estrogen-dependent disease that can lead to chronic pain and subfertility. Endometriotic lesions found
in different locations are heterogeneous and may represent a collection of related but distinct conditions. Whether there is
a relationship between hormonal contraceptive (HC) use and endometriosis is still controversial. The purpose of this study
was to determine whether HC use affected the prevalence of endometriotic lesions differently based on lesion location. Data
was retrospectively collected from 161 patients presenting to the Berne University Women’s Hospital between 2008 and 2012
for laparoscopic investigation. Women with histologically proven endometriosis were included in the study and patients were
grouped according to lesion location and HC use. The results of the study indicate that HC users are significantly less likely to
have endometriotic lesions on the ovaries, although in contrast, no difference was observed in the incidence of lesions in the
rectovaginal septum (RVS) or peritoneal region. In addition, women using HC who were diagnosed with endometriotic lesions on
the peritoneum were significantly younger than women with lesions in other locations. In conclusion, women with endometriosis
who are currently using HC are less likely to have ovarian endometriotic lesions than in alternate locations.
1. Introduction
Endometriosis is an estrogen-dependent disease defined by
the presence, growth, and invasion of endometrial epithelial
and stromal cells outside the uterine cavity that can lead to
chronic pelvic pain and a reduced fecundity. It is an extremely
prevalent condition with up to 10% of reproductive age
women suffering from the disease [1] with an even higher
incidence amongst infertile women [2] and adolescent girls
with chronic pelvic pain [3]. Current first line treatment
involves the induction of a hypoestrogenic state through the
use of hormonal contraceptives (HC) or gonadotropin releas-
ing hormone agonists (GnRHa). If unsuccessful the endo-
metriotic lesions must be removed surgically.
Although the exact aetiology of endometriosis is not
yet clear, certain factors such as lifestyle, nutrition, genetic
polymorphisms, and environmental pollutants [4–6] are
known to increase the potential for lesions development.
Given the estrogen dependence of the diseaseHCuse has also
been investigated. Currently, however, the link between HC
use and endometriosis is still debated as conflicting reports
have shown both a reduced [7, 8], and increased risk [9, 10]
as well as no association at all [11–13].
It is possible that the effects of HC use in endometriosis
development are not yet clear because the inherent hetero-
geneity of endometriotic lesions that develop at different
regions has not yet been sufficiently accounted for in these
studies. Ectopic endometrial lesions can develop in multiple
locations throughout the body with some examples even
recorded in the lungs [14] and brain [15]. Predominantly,
however, endometriotic lesions are found within the peri-
toneal cavity and can be broadly separated into three main
regions: the rectovaginal septum (RVS), the peritoneum,
and the ovaries. Biochemical and histological data show
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significant differences between lesions that develop at differ-
ent locations leading to suggestions that lesions from these
locations may have distinct pathophysiologies and should be
classed as separate entities [16]. Moreover, lesions can occur
in either one or more of these regions, and it is not yet
clear whether multiple lesions are established separately, or
their growth is facilitated by the accompanying inflammatory
reaction.
Endometriosis is a disease of reproductive age women
and a significant portion of this population use HC for both
fertility control and the treatment of pathological condi-
tions. The heterogeneity of endometriotic lesions suggests
endometriosis could be considered a collection of related, but
independent diseases, and thus, a thorough understanding
of the effects of hormonal treatments and whether they are
dependent on the specific presentation of the endometriotic
lesion is vital. We have therefore performed a retrospective
analysis of data collected fromwomenpresenting to our clinic
to determine the prevalence of endometriotic lesions and
whether this is significantly affected by HC use.
2. Materials and Methods
2.1. Patient Data. A cross sectional study was performed
with data collected retrospectively fromwomen presenting to
the Bern University Women’s Hospital during 2008–2012 for
laparoscopic investigation of chronic pelvic pain or idiopathic
infertility. Institutional ethics review board approval was
obtained and women were included in the study if they
provided informed consent and had a lesion removed during
surgery that was histologically confirmed as endometriosis.
All surgery was performed during the proliferative phase and
the patient was staged according to the revised American
Fertility Society Score (rAFS) [17]. The lesion locations
were noted by the surgeon during the operation and were
subsequently grouped into one of three possible regions; the
RVS, ovarian, or peritoneum, as described previously [18].
Medical records were searched for relevant data.
During the study period we received informed con-
sent from a total of 359 women, 213 of which had tissue
excised during surgery and at least one lesion subsequently
confirmed as endometriosis via histological examination. A
further 52 women reported GnRHa use prior to surgery and
were excluded from the study, resulting in a total of 161
women. The age range of women included in the study was
19–51 years with a mean of 32.56 ± 0.46 (Mean ± SEM).
To determine the prevalence of endometriotic lesions at
the different locations, both with and without HC use, two
separate groupings of women were made. The initial analysis
was performed by dividing all women into one of two groups
based on the presence or absence of a lesion in the defined
region. Therefore, if a woman had a lesion on the ovaries,
irrespective of whether additional lesions were identified at
other locations, they were grouped as ovarian. If no lesion
was present on the ovary the women were grouped as non-
ovarian. This was repeated for both the peritoneal and RVS
regions.
Grouping the women based on the exact region or
combination of regions that endometriotic lesions were
found allowed further analyses with more stringently defined
groups. Based on this criteria, seven groups in total were
possible, three of which represent single locations: (i) ovarian,
(ii) RVS, or (iii) peritoneal, and four groups that represented
combined regions: (i) peritoneal and ovarian, (ii) peritoneal
and RVS, (iii) ovarian and RVS, or (iv) all three locations.
Hormonal treatment was determined by the self-
reporting of women prior to surgery. HC use was split into
either current or non-use. Current use was defined as use
prior to and within the three months leading up to surgery,
and non-use was defined as no use for a minimum of three
months prior to surgery. Contraceptive use included all
treatments used to prevent birth including oral (combined
and gestagen only) and vaginal progesterone.
2.2. Statistical Analysis. Mean age was compared between
two groups with a Student’s 𝑡-test and between three groups
with a one-way analysis of variance (ANOVA) test with a
post-hoc Bonferroni’s multiple comparison between groups.
A Fisher’s exact test was used to compare the number of
women grouped by the presence or absence of endometriotic
lesions within each region and the comparison between
single and multiple lesions. A Chi-squared test was used
to analyse the difference in prevalence between the three
distinct regions (peritoneal, RVS, and ovarian). All statistical
tests were performed with GraphPad Prism 5 for Mac OSX
and the results were considered significant if the 𝑃 value was
below 0.05.
3. Results
3.1. The Incidence of Endometriotic Lesions at Different Loca-
tions and the Age of Patients. In 81 of the 161 women (81/161;
50.3%) an endometriotic lesion was found in only one of
the three defined regions, while 80 patients (80/161; 49.7%)
had endometriotic lesions in more than one (multiple) of
the defined regions. The most common single region was the
peritoneum with lesions found in 37 (37/161; 23.0%) women.
The RVS (22/161; 13.7%) and ovarian (22/161; 13.7%) region
had a similar incidence with 22 each. The most common
combination of multiple regions was the peritoneum and
ovaries with 42 (42/161; 26.1%) occurrences, followed by a
combination of all three regions with 21 (21/161; 13.0%) cases.
A combination of lesions in the peritoneum and RVS was
found in 14 (14/161; 8.7%)women and the combination of RVS
and ovarian lesions was uncommon with only 3 (3/161; 1.9%)
cases observed in the total study population (Table 1).
Of the 161 women included in this study 88 (88/161,
54.7%) were non-HC users, whereas 73 (73/161, 45.3%)
were HC users. The mean age of the HC users (30.66 ±
0.66) was significantly younger (𝑃 = 0.0001) than women
who were non-HC users (34.14 ± 0.60). When ages were
compared between the absence vs. presence groups there was
a significant difference (𝑃 = 0.0003) in the peritoneal group
with HC users (29.49 ± 0.79, 𝑛 = 49) younger than non-HC
users (33.43 ± 0.70, 𝑛 = 61). A similar difference was also
observed in the ovarian group, as HC users (31.41 ± 1.15, 𝑛 =
32) were significantly younger (𝑃 = 0.0218) than non-HC
users (34.09 ± 0.72, 𝑛 = 57). In the single lesion groups, the
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Table 1: The incidence and mean age of patients with endometriotic lesions at defined locations in both the current HC use or non-HC use
groups.
𝑛 (%) Age 𝑃
All No HC HC
All women 161 88 73
Age 32.56 ± 0.46 34.14 ± 0.60 30.66 ± 0.66 0.00011
Absence versus presence
Peritoneal 110 31.67 ± 0.55 (𝑛 = 110) 33.43 ± 0.70 (𝑛 = 61) 29.49 ± 0.79 (𝑛 = 49) 0.00031
RVS 58 33.28 ± 0.71 (𝑛 = 58) 34.30 ± 0.93 (𝑛 = 30) 32.18 ± 1.105 (𝑛 = 28) 0.13401
Ovarian 89 33.12 ± 0.56 (𝑛 = 89) 34.09 ± 0.72 (𝑛 = 57) 31.41 ± 1.15 (𝑛 = 32) 0.02181
𝑃 value 0.09712 0.70332 0.07712
Single region 81/161 (50.3) 32.47 ± 0.85 (𝑛 = 81)
Peritoneal 37/161 (23.0) 29.97 ± 1.07 (𝑛 = 37) 33.36 ± 1.71 (𝑛 = 14) 27.91 ± 1.20 (𝑛 = 23) 0.01141
RVS 22/161 (13.7) 34.4 ± 1.2 (𝑛 = 22) 36.09 ± 1.55 (𝑛 = 11) 32.73 ± 1.81 (𝑛 = 11) 0.17361
Ovarian 22/161 (13.7) 34.73 ± 1.3 (𝑛 = 22) 35.50 ± 1.64 (𝑛 = 16) 32.67 ± 2.03 (𝑛 = 6) 0.35071
Single location (𝑃 value) 0.00582 0.49322 0.04342
Multiple regions 80/161 (49.7) 32.65 ± 0.58 (𝑛 = 80)
Peritoneal and ovarian 42/161 (26.1) 32.88 ± 0.80 (𝑛 = 42) 33.96 ± 0.99 (𝑛 = 27) 30.93 ± 1.22 (𝑛 = 15) 0.06801
Peritoneal and RVS 14/161 (8.7) 32.57 ± 1.67 (𝑛 = 14) 32.83 ± 3.14 (𝑛 = 6) 32.38 ± 1.95 (𝑛 = 8) 0.89851
RVS and ovarian 3/161 (1.9) 33.67 ± 4.41 (𝑛 = 3) — 33.67 ± 4.41 (𝑛 = 3) —
Peritoneal, ovarian, & RVS 21/161 (13.0) 32.10 ± 0.94 (𝑛 = 21) 32.71 ± 1.14 (𝑛 = 14) 30.86 ± 1.70 (𝑛 = 7) 0.36681
Multiple location (𝑃 value) 0.93332 0.73892 0.78732
Single versus multiple (𝑃 value) 0.84621
1Comparison of the mean age between HC users and non-HC users, as well as between the single and the multiple regions, was performed by a Student’s 𝑡-
test. 2Comparison of the mean age between women with lesions in different locations, as well as for both the single and multiple regions, was performed by a
one-way ANOVA test with a post-hoc Bonferroni’s multiple comparison test.
women with peritoneal lesions that were HC users (27.91 ±
1.20, 𝑛 = 23) were significantly younger (𝑃 = 0.0114) com-
pared to non-HC users (33.36 ± 1.71, 𝑛 = 14) (Table 1).
When comparing ages across lesion locations there was
no significant difference (𝑃 = 0.0971) between the ages of
women based on presence of a lesion at the defined region. If
the samples were split by HC and non-HC use, again, there
was no significant difference between the age of the women
based on the presence of a lesion. When only women with
a lesion in a single location were taken into account a one-
way ANOVA test confirmed a significant difference between
the mean ages (𝑃 = 0.0058). A post-hoc Bonferroni’s Multiple
comparison test indicated that womenwith peritoneal lesions
were significantly younger (29.97±1.07, 𝑛 = 37) than women
with lesions in either the RVS (34.40±1.20, 𝑛 = 22; 𝑃 < 0.05)
or the ovaries (34.73 ± 1.30, 𝑛 = 22; 𝑃 > 0.05). When
these women were further split based on HC use a one-
way ANOVA test indicated a significant difference existed
between the HC users (𝑃 = 0.0434) but not in the non-HC
users (𝑃 = 0.4932) (Table 1).
3.2. Hormonal Contraceptive Use and the Region Specific
Prevalence of Endometriotic Lesions. Of the entire study
population, 54.7% (88/161) of the womenwere currently non-
HC users compared to 45.3% (73/161) who were current HC
users. Of the 81 women with endometriotic lesions in a single
region, 41 (41/81; 50.6%) were non-HC users, whereas 40
(40/81; 49.4%) were current HC users. Of the 80 women with
endometriotic lesions in multiple regions 47 (47/80; 58.8%)
were non-HC users compared to 33 (33/80; 41.3%) who were
current HC users. The difference between the prevalence of
lesions in either single or multiple locations based on current
HC use was not significant (𝑃 = 0.3435) (Table 2).
When grouped via the simple presence or absence of
endometriotic lesions the most common location was the
peritoneal region with 110 cases (110/161; 68.3%). Ovarian
lesions were detected in 89 cases (89/161; 55.3%) and RVS
lesions in 58 (58/161; 36.0%) cases. In the study group, there
was a significantly lower probability (OR = 0.45, 95% CI
0.24–0.88, 𝑃 = 0.0167) of having an endometriotic lesion
present (32/89; 36.0%) on the ovary compared to it being
clear of a lesion (40/72; 55.6%) if the womenwere current HC
users. In contrast, no significant effect of current HC use was
observed on the incidence of endometriotic lesions in either
the peritoneum or the RVS (Table 2).
To confirm an association between the reduced preva-
lence of ovarian endometriotic lesions and HC use we
selected women with lesions in a single region only and
used a Chi-squared test to analyse the distribution amongst
these locations between current HC users and non-HC users.
In these women, the incidence of ovarian endometriotic
lesions, compared to the peritoneum and the RVS, was also
significantly lower (𝑃 = 0.0347) with current HC use
(Table 3).
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Table 2: Hormonal contraceptives and the presence of endometriotic lesions in defined regions.
Single region, 𝑛 (%) Multiple region, 𝑛 (%) OR (95% CI) 𝑃 value
Single versus multiple regions
All 81 80
No hormone 41 (50.6) 47 (58.8)
HC 40 (49.4) 33 (41.3) 0.72 (0.39–1.34) 0.3435
Absence, 𝑛 (%) Presence, 𝑛 (%) OR (95% CI) 𝑃 value
Ovarian
All 72 89
No hormone 32 (44.4) 57 (64.0)
HC 40 (55.6) 32 (36.0) 0.45 (0.24–0.88) 0.0167
Peritoneal
All 51 110
No hormone 28 (54.9) 61 (55.4)
HC 23 (45.1) 49 (44.5) 0.98 (0.50–1.91) 1.000
RVS
All 101 58
No hormone 57 (56.4) 30 (51.7)
HC 44 (43.6) 28 (48.3) 1.21 (0.63–2.31) 0.6210
A Fisher’s exact test was used to determine if the incidence of endometriotic lesions in particular locations was significantly different under HC use.
Table 3: Prevalence of women with endometriotic lesions in single regions only with and without hormonal contraceptive use.
Ovarian, 𝑛 (%) Peritoneal, 𝑛 (%) RVS, 𝑛 (%) 𝑃 value
Single location cases
No hormone 𝑛 (%) 16 (39.0) 14 (34.1) 11 (26.8) 0.0347
HC 𝑛 (%) 6 (15.0) 23 (57.5) 11 (27.5)
A Chi-squared test was used to determine whether the incidence of endometriotic lesions in different locations was significantly different under HC use.
4. Conclusion
The relationship between HC use and endometriosis is
still controversial. We proposed that the heterogeneity of
endometriotic lesions that are found in different regions
might contribute to the disparity in results previously
reported. This study reports that current HC users are less
likely to have endometriotic lesions on the ovaries, whereas
in contrast, no difference was observed in the incidence of
lesions in either the RVS or peritoneal regions. The results
therefore suggest that HC use may affect endometriotic
lesions at separate locations differently and may be indicative
of distinct pathophysiologies for lesions that develop at
separate locations. Although this study only represents a
small sample set it also suggests a potentially protective effect
of HC use on the development of ovarian endometriotic
lesion, which should be investigated further.
Previous evidence indicates that significant biochemical
and anatomical differences exist between lesions at different
locations and that it is possible that lesions found in the
peritoneal cavity, the ovaries, and in the RVS all have a
distinct pathophysiologies [16]. HC use has been suggested
to influence the incidence of endometriosis [19]; however
whether it affects all lesions equally has not been assessed and
thusmay offer further evidence for distinct pathophysiologies
based on the location of the lesions or underlying tissue.
This study was therefore designed to assess the relationship
between endometriosis and HC use while accounting for the
heterogeneity that may exist between endometriotic lesions
that develop in separate regions. A particular strength of
this study is that we have identified the location of every
lesion removed from the patients and as such have been
able to perform a dual analysis with two distinct patient
groupings. Firstly, an analysis was performed based simply
on the presence or absence of a lesion at the defined location.
Secondly, a smaller but more stringent grouping was made
that included only women with lesions in a single region.
By using the larger cohort of women based simply on the
presence or absence of a lesion,we had larger sample numbers
in each group and therefore more statistical power. The
results of this analysis show it was significantly less likely for
women who have endometriosis and are using HC to have a
lesion on the ovaries than either the peritoneal cavity or the
RVS. Subsequently, by studying women with lesions confined
to a single region only we have analysed a smaller but
more distinct subgroup that may help to eliminate potential
confounding factors introduced when women have more
than one affected region. Most importantly, the results of this
analysis confirmed those of the larger cohort.
Previously, only a limited number of studies on HC use
and endometriosis have taken into account the location of
the lesions, or when they have done so this aspect was not
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a primary focus as a potential source of heterogeneity. These
studies have also used different methods of grouping patients
and as such have also reported disparate results. One study
by Chapron et al. (2011) examined both the location of the
lesion as well as the primary reason for HC prescription.
This study found that past, but not current HC use, was
frequently associated with the development of deep infiltrat-
ing endometriosis (DIE) [20], particularly when prescribed
for severe primary dysmenorrhea, but found no relation-
ship with HC use and endometriomas. Contrary to our
study, this report grouped women based on the most serious
lesion identified, rather than their presence or absence.
Superficial peritoneal endometriosis was considered the least
severe, followed by endometrioma andfinallyDIE as themost
severe. Therefore, based on these groupings, a number of
women with endometriomas may have also been included in
the DIE group, or women with peritoneal lesions may have
been included in both the endometrioma andDIE group.This
represents a significant difference from the groupings per-
formed in our study and could explain the variation in results.
Another study that focused primarily on environmental risk
factors found a lower but nonsignificant previous use of HC
with womenwho had either peritoneal or DIE.This study did
not report on ovarian endometriosis [21].
It must also be noted that in this study we have only
analysed women with histologically confirmed endometrio-
sis. We have not analysed the incidence of endometriosis in
the population, but rather the incidence of endometriosis at
defined regions in a population of women with endometrio-
sis. By performing the analysis in this way we have eliminated
a non-endometriosis group that is notoriously difficult to
establish as a homogenous sample and have focused on the
incidence of endometriosis at different locations in a group of
women known to be susceptible to endometriosis. Whether
HC use has a similar effect on women that are not originally
susceptible to endometriosis is not addressed in this study.
Aswith all studies some inherent weakness and limitation
are also present and thus should be discussed. Firstly, the
mean age of the current HC users was significantly younger
than those who were non-HC users. A further analysis of
the mean ages shows that women with lesions in both the
peritoneal cavity and the ovaries, but not the RVS, are also sig-
nificantly younger in the current HC users group compared
to the non-HC users, although in the single lesion group this
difference exists only in the peritoneal samples and not the
ovarian or RVS samples. This difference between the age of
the current HC users and non-HC users is not surprising
as the primary reason for HC use (contraception) will be
more common amongst youngerwomen.These demographic
differences in the use of HC will therefore always make this
difficult to resolve in such studies.
This difference in age between the current HC users and
non-HC users also raises the possibility that the lower inci-
dence of ovarian endometriotic lesions observed in women
using HC may be due to their younger age. Previous studies
have found that the incidence of endometriosis increases with
increasing age, with one study showing a peak between 30
and 35 [7] and another showing a peak between 40 and 44
[22], although both suggest that a difference of at least 5 years
is required to achieve a significant difference. While there is
a statistically significant difference between the ages of the
two groups in our study, the entire difference is less then
5 years which is unlikely to be sufficient to alter incidence
of the disease, particularly as a delay in the diagnosis from
the original inception of the lesion can be up to 11 years
[23]. In addition, although the age difference was statistically
significant with both the peritoneal and ovarian groups we
only observed a difference in the incidence of lesions based on
current HC use in the ovarian group and not the peritoneal
group. In fact, the incidence of ovarian endometriosis in
current HC users was still much lower than that observed
in peritoneal lesions even though the mean age of women
with peritoneal lesions was significantly lower than that of
women with ovarian lesions. The role of age in the incidence
of endometriotic lesions at different locations should be taken
into account when designing further studies to analyse the
effect of HC use on lesions from different locations.
Previous studies have also suggested that the influence of
HC use on the incidence of endometriotic lesions depends on
whether the usage is still current. Women currently taking
HC have a reduced incidence of endometriosis, whereas
women who had stopped taking HC for over 12 months have
an increased incidence [7, 22]. Past users were also shown
to have an increased incidence of DIE, but not other types
of endometriosis [20]. A meta-analysis of 18 studies also
concluded that there was an increased incidence in past users,
but a decreased incidence in current users [19]. As previous
studies have shown that the duration of HC use is not related
to disease status [7], but rather whether or not use is current,
we focused only on current use and whether it influences the
incidence of endometriotic lesions at different locations. We
used a three-month period to establish current use, as this
is a period commonly needed for a stable menstrual cycle to
be reestablished after hormonal control. Although we used
this three-month cut-off we do not suggest that abstinence
fromHC for three months is sufficient to allow the growth of
endometriosis. It is most likely that non-HC users have not
taken HC for a period much longer than this. Unfortunately,
we did not have a large enough sample size to analyse the
impact of the duration of use.
Multiple theories have been proposed to explain the
aetiology of endometriosis [24] and although retrograde
menstruation is the most widely accepted it cannot explain
the occurrence of all lesions, particularly those that occur
in the absence of a functioning endometrium [25, 26],
supporting the possibility ofmultiple aetiologies. It is possible
that the results of this study are a reflection of the inherent
differences that exist in lesions that develop at different
anatomical locations and that these lesions may have variable
aetiologies potentially influenced by HC use. This is not
surprising given the variability of the underlying tissue where
endometriotic lesions can be found.
The results of this study therefore showed that endometri-
otic lesions are less likely to be found on the ovaries than
in other locations in current HC users. These results suggest
a potential protective effect of HC use that differs based on
the anatomical locations most susceptible to the disease. It
is important to note that the results do not suggest that HC
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use protects against endometriosis, but rather only that itmay
affect development at separate locations differently. It must
be remembered, however, that no causality can be drawn
from this study, and further work should be performed to
understand exactly what the link is between HC use and the
development of location specific endometriotic lesions.
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